Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK3 | P27361 | 2/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.41 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.39 |
| ▸ | MAP2K1 | Q02750 | 5/20 | 0.38 |
| ▸ | JAK1 | P23458 | 10/20 | 0.35 |
| ▸ | TYK2 | P29597 | 10/20 | 0.35 |
| ▸ | JAK2 | O60674 | 5/20 | 0.35 |
| ▸ | PDE4D | Q08499 | 4/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | MAP2K2 | P36507 | 1/20 | 0.34 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL691583 | 0.91 | PTK2 (0.49) | MAPK3MAPK1PTK2MAP2K1JAK1 | |
| SCHEMBL691711 | 0.84 | PTK2 (0.51) | MAPK3MAPK1PTK2MAP2K1JAK1 | |
| SCHEMBL692007 | 0.81 | PTK2 (0.49) | MAPK3MAPK1PTK2MAP2K1JAK1 | |
| SCHEMBL1292976 | 0.80 | PTK2 (0.60) | MAPK3MAPK1PTK2MAP2K1JAK1 | |
| SCHEMBL1293166 | 0.75 | PTK2 (0.51) | MAPK3MAPK1PTK2MAP2K1JAK1 | |
| SCHEMBL690575 | 0.74 | PTK2 (0.58) | MAPK3MAPK1PTK2JAK1TYK2 | |
| SCHEMBL690567 | 0.70 | PTK2 (0.50) | PTK2MAP2K1JAK1TYK2 | |
| SCHEMBL691964 | 0.70 | MAPK1 (0.63) | MAPK3MAPK1PTK2JAK1TYK2 | |
| SCHEMBL1293001 | 0.70 | MAPK1 (0.61) | MAPK3MAPK1PTK2JAK1TYK2 | |
| SCHEMBL1293133 | 0.69 | PTK2 (0.61) | MAPK3MAPK1PTK2JAK1TYK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100113475-A1 | PYRAZOLYLAMINOPYRIDINES AS INHIBITORS OF FAK | GLAXOSMITHKLINE LLC | 2010-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113475-A1 | PYRAZOLYLAMINOPYRIDINES AS INHIBITORS OF FAK | PTK2, PAK1, CTTN | MAPK3 64/4885MAPK1 221/4885PTK2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.